Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE32874 E
Publication typeGrant
Application numberUS 06/860,894
Publication dateFeb 21, 1989
Filing dateMay 8, 1986
Priority dateNov 1, 1982
Fee statusPaid
Also published asCA1216518A1, DE3380112D1, EP0108588A2, EP0108588A3, EP0108588B1, US4447415
Publication number06860894, 860894, US RE32874 E, US RE32874E, US-E-RE32874, USRE32874 E, USRE32874E
InventorsGail A. Rock, George A. Adams
Original AssigneeGail A. Rock
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Suspension in balanced salt solution in plastic bag; treating thrombocytopenia
US RE32874 E
Abstract
Blood platelet concentrate in a plasma-free medium. Method for storage of blood platelets in a plasma-free medium which comprises centrifuging plasma to obtain a platelet pellet, removing the supernatant plasma, and resuspending the platelet pellet in a balanced salt medium. The balanced salt medium in an isotonic solution and may be selected from well known physiologically tolerable salt mediums. Additives to enhance platelet storage can be added to the salt medium.
Images(7)
Previous page
Next page
Claims(35)
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A method for the preparation of .[.a.]. .Iadd.an essentially plasma-free .Iaddend.blood platelet concentrate for administration to animals which comprises
centrifuging plasma to obtain a platelet pellet,
removing the supernatant plasma, and
resuspending the platelet pellet in a medium consisting essentially of: a balanced, physiological compatible, saline solution; an anticoagulant; and one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
2. A method as claimed in claim 1 wherein the nutrients are selected from fructose, adenine or acetyl CoA.
3. A method as claimed in claim 1 wherein the reversible inhibitors for platelet activation are selected from indomethacin, quinacrine or vitamin E.
4. A method as claimed in claim 1 wherein the substances to raise cyclic adenosine monophosphate levels are selected from prostaglandins E1, D2 or I2.
5. A method as claimed in claim 1 wherein the buffering agents are selected from phosphate or amino acids.
6. A method as claimed in claim 5 wherein the amino acids are selected from histidine, cysteine, tyrosine, lysine or arginine.
7. A method as claimed in claim 1 wherein the balanced salt medium is selected from Spinner salt solution, Tyrode's solution, Seligmann's balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solutions or Puck's saline.
8. A method as claimed in claim 1 wherein the balanced salt medium is a Tyrode's solution.
9. A method as claimed in claim 6 wherein the Tyrode's solution contains a phosphate buffer or a histidine buffer.
10. A method as claimed in claim 6 wherein extraction and a washing step is used to remove plasma from platelets prior to final suspension in the Tyrode's solution.
11. A method as claimed in claim 7 wherein extraction is used to remove plasma from platelets prior to final suspension in the modified Tyrode's solution.
12. A method as claimed in claim 1 wherein the plasma is human plasma.
13. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole blood or by apheresis.
14. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole human blood or by apheresis on a human donor.
15. A method as claimed in claim 1 wherein the plasma is human plasma.
16. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole blood or by apheresis.
17. A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole human blood or by apheresis on a human donor.
18. .[.A.]. .Iadd.An essentially plasma-free .Iaddend.platelet concentrate composition for administration to animals comprising blood platelets suspended in a medium consisting essentially of:
a balanced, physiologically compatible, saline solution;
an anticoagulant; and
one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
19. A platelet concentrate as claimed in claim 18 wherein the nutrients are selected from fructose, adenine or acetyl CoA.
20. A platelet concentrate as claimed in claim 18 wherein the reversible inhibitors for platelet activation are selected from indomethacin, quinacrine or vitamin E.
21. A platelet concentrate as claimed in claim 18 wherein the substances to raise cyclic adenosine monophosphate levels are selected from prostaglandins E1, D2 or I2.
22. A platelet concentrate as claimed in claim 18 wherein the buffering agents are selected from phosphate or amino acids.
23. A platelet concentrate as claimed in claim 22, wherein the amino acids are selected from histidine, cysteine, tyrosine, lysine or arginine.
24. A platelet concentrate as claimed in claim 18, wherein the balanced salt medium is selected from Spinner salt solution, Tyrode's solution, Seligmann's balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solutions or Puck's saline.
25. A platelet concentrate as claimed in claim 18 wherein the balanced salt medium is a Tyrode's solution.
26. A platelet concentrate as claimed in claim 25 wherein the Tyrode's solution contains a phosphate buffer or a histidine buffer.
27. A platelet concentrate as claimed in claim 18 wherein the plasma is human plasma.
28. A platelet concentrate as claimed in claim 18 wherein the human plasma is derived from freshly collected whole blood or by apheresis on a human donor. .Iadd.
29. An essentially plasma-free storage-stable package of blood platelets, which comprises a concentrate of blood platelets suspended in a volume of physiologically acceptable salt solution, said suspension being sealedly enclosed within a blood storage member. .Iaddend. .Iadd.30. The storage-stable package as defined by claim 29 which is devoid of a buffering agent. .Iaddend. .Iadd.31. The storage-stable package as defined by claim 29 which is devoid of an anticoagulant. .Iaddend. .Iadd.32. The storage-stable package as defined by claim 29, said blood storage member comprising a blood collection and storage bag. .Iaddend. .Iadd.33. The storage-stable package as defined by claim 32, said blood collection and storage bag being highly permeable. .Iaddend. .Iadd.34. The storage-stable package as defined by claim 29, said blood storage member comprising a plastic blood collection and storage bag. .Iaddend. .Iadd.35. The storage-stable package as defined by claim 29, which further comprises a buffering agent. .Iaddend. .Iadd.36. The storage-stable package as defined by claim 29, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend.
.Iadd. 7. The storage-stable package as defined by claim 36, wherein the physiologically compatible salt solution is Tyrode's solution. .Iaddend. .Iadd.38. The storage-stable package as defined by claim 37, wherein Tyrode's solution contains a phosphate buffer or a histidine buffer. .Iaddend. .Iadd.39. The storage-stable package as defined by claim 29, wherein the blood platelets are human blood platelets. .Iaddend. .Iadd.40. The storage-stable package as defined by claim 39, wherein the blood platelets are derived from platelet-rich plasma from whole blood or by apheresis on a human donor. .Iaddend. .Iadd.41. The storage-stable package as defined by claim 29, further comprising an anticoagulant. .Iaddend. .Iadd.42. The storage-stable package as defined by claim 29, further comprising saline-citrate-buffer. .Iaddend. .Iadd.43. The storage-stable package as defined by claim 29, further comprising
saline-citrate-buffer-nutrient. .Iaddend. .Iadd.44. A composition of matter comprising an essentially plasma-free storage-stable concentrate of blood platelets suspended in a volume of physiologically acceptable salt solution, said composition exhibiting no worse than normal platelet aggregation. .Iaddend. .Iadd.45. The composition of matter as defined by claim 44, further comprising an additive adopted to enhance platelet function under conditions of storage, or to prolong the storage life thereof. .Iaddend. .Iadd.46. The composition of matter as defined by claim 45, which said additive is a buffering agent. .Iaddend. .Iadd.47. The composition of matter as defined by claim 44, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend. .Iadd.48. The composition of matter as defined by claim 47, wherein the physiologically compatible salt solution is Tyrode's
solution. .Iaddend. .Iadd.49. The composition of matter as defined by claim 48, wherein Tyrode's solution contains a phosphate buffer or a histidine buffer. .Iaddend. .Iadd.50. The composition of matter as defined by claim 44, wherein the blood platelets are human blood platelets. .Iaddend. .Iadd.51. The composition of matter as defined by claim 50, wherein the blood platelets are derived from platelet-rich plasma from whole blood or by apheresis on a human donor. .Iaddend. .Iadd.52. The composition of matter as defined by claim 44, further comprising an anticoagulant. .Iaddend. .Iadd.53. The composition of matter as defined by claim 44, further comprising saline-citrate-buffer. .Iaddend. .Iadd.54. The composition of matter as defined by claim 44, further comprising saline-citrate-buffer-nutrient. .Iaddend. .Iadd.55. A method for the storage of essentially plasma-free blood platelets, which comprises confining a concentrate of said blood platelets suspended in a volume of physiologically acceptable salt solution within a blood storage member,
for a period of time of at least 72 hours. .Iaddend. .Iadd.56. The method as defined by claim 55, comprising confining the suspension within said blood storage member under conditions of agitation. .Iaddend. .Iadd.57. The method as defined by claim 55, wherein a buffering agent is contained in the storage member. .Iaddend. .Iadd.58. The method as defined by claim 55, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend. .Iadd.59. The method as defined by claim 58, wherein the physiologically compatible salt solution is Tyrode's solution. .Iaddend. .Iadd.60. The method as defined by claim 59, wherein Tyrode's solution contains a phosphate buffer or a histidine buffer. .Iaddend. .Iadd.61. The method as defined by claim 55,
wherein the plasma is human plasma. .Iaddend. .Iadd.62. The method as defined by claim 61, wherein the plasma is derived from human whole blood or by apheresis on a human donor. .Iaddend. .Iadd.63. The method as defined by claim 55, wherein the storage member is highly permeable. .Iaddend. .Iadd.64. The method as defined by claim 55, wherein an anticoagulant is contained in the storage member. .Iaddend. .Iadd.65. The method as defined by claim 55, wherein saline-citrate-buffer is present within the storage member. .Iaddend. .Iadd.66. The method as defined by claim 55, wherein saline-citrate-buffer-nutrient is present within the storage member. .Iaddend. .Iadd.67. A method for the treatment of thrombocytopenia in a patient in need of such treatment, which comprises infusing into such patient an effective amount of an essentially plasma-free concentrate of blood platelets suspended in a volume of
physiologically compatible salt solution. .Iaddend. .Iadd.68. The method as defined by claim 67, wherein the physiologically compatible salt solution is selected from the group consisting of Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solution or Puck's saline. .Iaddend. .Iadd.69. The method as defined by claim 68, wherein the physiologically compatible salt solution is Tyrode's solution. .Iaddend. .Iadd.70. The method as defined by claim 69, wherein Tyrode's solution contains a phosphate buffer or histidine buffer. .Iaddend.
Description
BACKGROUND OF THE INVENTION

This invention is concerned with a method for the storage of blood platelets in a plasma-free medium. Also described is a platelet concentrate obtained by this method.

Thrombocytopenia means low platelet counts in the circulatory system. Persons with this disease have a tendency to bleed as do hemophiliacs, except that the bleeding is usually from many small capillaries rather than from large vessels as in hemophilia. Such persons suffer small punctate hemorrhages throughout all the body tissues. The skin of such a person will exhibit many small, purplish blotches. Platelets are especially important for repair of minute breaks in capillaries and other small vessels. Platelets aglutinate to fill such ruptures without actually causing clots.

Normally, excessive bleeding does not occur until the number of platelets in the blood falls below a value of approximately 70,000 per cubic millimeter rather than the normal of 150,000 to 350,000.

At the present time, persons who have low platelet counts are supported by infusion of platelet concentrates. Platelet concentrates contain on average 61010 platelets suspended in a volume of 50-60 ml of plasma. Larger platelet concentrates can be obtained using apheresis machinery, in which case the concentration is in the range of 41011 and the plasma volume may reach 200-300 ml. Platelet concentrates can be kept for 3, 5 or even 7 days, depending on the type of bag and mode of rotation used.

There are generally speaking two types of blood collection and storage bags available. One type permits storage of platelets in plasma for up to 3 days while another type permits storage of platelets in plasma for up to 5 days and sometimes up to 7 days. The latter type is generally used for research purposes. In addition it should be noted that platelet storage bags must not contain the plasticizer di-2-ethyl-hexylphthalate and they should be highly permeable. While stored, all bags are subjected to rotation on a continuous basis which can be rotational about a transverse axis or horizontal and reciprocal or horizontal and circular.

SUMMARY OF THE INVENTION

The present inventors have developed a method whereby platelets can be stored in a medium other than plasma while still retaining the functional characteristics of platelets stored in plasma. The technique involves centrifugation of the plasma to obtain a platelet pellet, removal of the supernatant plasma, and subsequent resuspension of the platelet pellet in a balanced salt medium.

Thus, the present invention provides a method for the preparation of a platelet concentrate which comprises centrifuging plasma to obtain a platelet pellet, removing supernatant plasma and resuspending the platelet pellet in a balanced salt medium.

The plasma can be derived from freshly collected while blood or may be collected using apheresis machinery, i.e. apheresis platelets. The blood or plasma is preferably collected from humans.

The balanced salt medium or isotonic solution is designed to provide the basic nutrients required for platelet support during storage and, as well, to enhance the environment above that obtained under plasma (physiological) conditions. More specifically, the isotonic solution or balanced salt medium comprises a conventional, physiologically tolerable isotonic solution to which various additional additives may be added to enhance platelet stability.

Examples of conventional balanced salt mediums or isotonic solutions which can be used for this purpose are Spinner salt solution (Eagle H, Science, 130:432 (1959)), Tyrode's (Tyrode, M. V., Arch. Intern. Pharmacodyn., 20:205 (1910)), Seligmann balanced salt solution (formula below), Earle's balanced salt solutions (Natl. Cancer. Inst. 4:167 (1943)), Dulbecco's phosphate buffered saline (J. Exp. Med., 98:167 (1954)), Hanks' balanced salt solutions (Proc. Soc. Exp. Biol. Med., 71:196 (1949)), modification-National Institutes of Health) Gey's balanced salt solutions (Amer. J. of Cancer, 27:55 (1936)), Puck's saline (Puck, T. T., Cieciura, S. J. and Robinson, A. J. Exp. Med., 108:945 (1958)).

The formula for Seligmann balanced salt solution is as follows:

______________________________________Component       mg/L______________________________________NaCl            7650.00KCl             200.00NaCO2.CH3           1500.00NaH2 PO4.H2 O           50.00KH2 PO4           100.00D-Glucose       1000.00NaHCO3     700.00Ascorbic Acid   3.00______________________________________

There are several advantages to using a balanced salt solution in place of plasma and these are as follows. The plasma can be recovered and can be used for other purposes involving protein fractionation or transfusion to patients. Plasma is an expensive commodity and generally in short supply. Replacement of the plasma as a supernatant for platelet storage would result in considerable saving of plasma (estimated 14,000 liters in Canada alone in 1982) throughout the world.

Another advantage is the possibility of enhancing the storage environment above that generally found for plasma. Platelets are collected into an anticoagulant solution whose pH and biochemical constituents are chosen to enhance red cell preservation and which therefore may not be of optimal composition for platelet storage.

Beside the economic advantages, there are considerable theoretical medical advantages to removal of plasma and resuspension of platelets in a plasma free medium:

i. Removal of plasma components that are potentially harmful to platelets such as glycolytic and proteolytic enzymes that remove membrane glycoproteins and thus cause premature clearance from the circulation;

ii. Reduce the risk of exposure to infectious agent;

iii. Reduced risk of immediate and delayed allergic responses of recipients;

iv. Greater control over environmental conditions, especially pH, ion concentration and volume;

v. Reduced variations in platelet concentrates that would enhance the confidence of physicians in platelet concentrates perhaps leading to therapeutic regimes requiring fewer platelet concentrates per treatment; and

vi. The addition of agents to the storage medium may further improve platelet function after storage or prolong the storage life of platelets.

The agents which can be added to the storage medium can include one or more of the following. Nutrients may be added to the medium, and may be selected from fructose and other sugars, adenine or acetyl CoA. These nutrients are substrates for the glycolytic or proteolytic enzymes on the platelet surface and prevent these enzymes from altering the platelet surface.

Another approach is to inhibit the above and other enzymes with reversible inhibitors that are diluted upon infusion into the circulatory system and hence no longer inhibitory. Examples of these compounds are indomethacin, quinacrine or vitamin E, all of which inhibit platelet activation during storage and perhaps increase storage life.

Yet another method to control platelet activation during storage is to raise cyclic adenosine monophosphate with exogenous prostaglandins E1, D2 or I2 which again have a short half-life in vivo and reversible effects on platelets.

Finally, the artificial medium can be buffered by addition to the medium of a number of agents all of which can safely be infused into patients. These include phosphate and the amino acids: histidine, cysteine, tyrosine, lysine or arginine. These amino acids have the ability to buffer at an alkaline pH of 9 while phosphate precipitates at this pH.

Thus, in summary the isotonic solution may contain nutrients to improve the storage life of the platelets, reversible inhibitors for platelet activation, substances to raise cyclic adenosine monophosphate levels and which have reversible effects on platelets, and buffering agents which can be safely infused into patients. Generally these additives are used in physiological salt concentrations.

By the present method, the storage of platelet concentrates in a plasma free medium can be effected for at least 72 hours and results can be obtained which are similar to or better than those currently found using standard conditions of storage in plasma.

In another aspect, this invention provides a platelet concentrate in a plasma-free medium, which medium is a balanced salt medium which is an isotonic solution. The solution may be modified with the previously described agents. The present platelet concentrates can be stored for the same amount of time as presently available plasma concentrates can be stored. Further the platelet concentrates in the non-plasma medium are about the same as for the plasma medium, that is, about 109 ml or 1012 /L.

DETAILED DESCRIPTION OF THE INVENTION

The following examples are used to illustrate the present invention. All parts and percentages are by weight unless otherwise specified.

Two series of experiments were carried out to show the effects of storing platelets in a non-plasma medium. The first series (A) uses extraction and a washing step to remove plasma from platelets prior to final suspension in a Tyrode's solution. The second series (B) uses only extraction of plasma and final suspension in a modified Tyrode's solution containing either extra phosphate buffer or histidine buffer.

EXAMPLE 1 Series A

Method:

Preparation of Platelet Concentrates: Platelet concentrates were prepared by acidification of a pool of platelet-rich plasma using 35 ml acid-citrate-dextrose anticoagulant to 230 ml of platelet-rich plasma, to yield a final pH of 6.4. This lower pH allows immediate resuspension of platelets concentrated by the normal centrifugation procedure of 3000 g for 5.5 minutes. The plasma was extracted and the platelets resuspended in a washing solution containing 0.5 mM EDTA in calcium and magnesium-free Tyrode's buffer, pH 6.4. After centrifugation at 3000 g for 5.5 minutes and extraction of supernatant, the platelets were resuspended in (Citrate-Phosphate-Dextrose anticoagulant) CPD Tyrode's solution or CPD-plasma at a final volume of 60 ml in P1-146 (plastic) bags (a trademark of Fenwall Company, Deerfield, Ill. 60015). The composition of the CPD-Tyrode's balanced salt solution is given in Table 1. These concentrates were stored at 22 C. in a horizontal shaker for testing after 3 days.

Platelet Aggregation: Aliquots from the platelet concentrates were diluted in pooled plasma containing CPD to a final concentration of 3108 platelets/μl. After incubating for one hour at 37 the platelet suspensions were aggregated by addition of one stimulus or simultaneous addition of pairs of stimuli. The stimuli and concentrations used were adenosine diphosphate (ADP) at 10-5 M, epinephrine at 510-5 M, collagen at 2.4 μg/ml, arachidonic acid at 10-4 M, and calcium ionophore A23187 at 510-6 M. All these are final concentrations in the platelet suspensions.

Results:

The results for the platelets washed and resuspended in CPD-Tyrode's (Table 2) and CPD-plasma (Table 3) and for unwashed normal platelet concentrates (Table 4) are presented. The reported values are means and standard errors of at least three determinations except for those aggregations using arachidonate. The platelets stored in CPD-Tyrode's had slightly reduced aggregation responses when compared to the two control preparations stored in CPD-plasma. All three preparations lost the ability to aggregate to collagen, epinephrine or ADP while retaining aggregation response to pairs of stimuli or ionophore. The response to all three preparations were identical when tested before storage, indicating the washing procedure did not acutely alter the platelets (data not shown).

EXAMPLE 2 Series B

Method:

Preparation of Platelet Concentrates: Platelet concentrates were prepared by the normal centrifugation procedure of 3000 g for 5.5 minutes (no ACD was added). The plasma was extracted and the platelets resuspended in CPD-Tyrode's-phosphate solution, CPD-Tyrode's-Histidine (see Table 1 for recipes) or CPD-plasma at a final volume of 60 ml in PL 145 bags. These concentrates were stored at 22 C. in a horizontal shaker for testing after 3 days.

Platelet Aggregation: All aggregations were performed as in Series A.

Results:

The results for the platelets washed and resuspended in CPD-Tyrode's-phosphate (Table 5), and CPD-Tyrode's-Histidine (Table 6) and for unwashed normal platelet concentrates (Table 4) are presented and show values equal to or better than for platelets stored in the usual way in plasma. The reported values are means and standard errors of at least three determinations except for those aggregations using arachidonate. There was no difference between the platelets stored in CPD-Tyrode's-Histidine, CPD-Tyrode's-phosphate and the preparations stored in CPD-plasma. As in Series A, all three preparations lost the ability to aggregate to collagen, epinephrine or ADP while retaining aggregation response to pairs to stimuli or ionophore. The responses of all three preparations were identical when tested before storage, indicating the washing procedure did not significantly alter the platelets (data not shown).

              TABLE 1______________________________________Composition of Some Artificial Mediums Used  CPD-     CPD-Tyrode's-                       CPD-Tyrode's-  Tyrode's Phosphate   Histidine______________________________________NaCl     120    mM      102   mM    102   mMKCl      2.4    mM      2.4   mM    2.4   mMNaHCO3    22.0   mM      10.0  mM    10.0  mMNaH2 PO4    0.4    mM      22.0  mM    --CaCl2    1.8    mM      1.8   mM    1.8   mMMgCl2    0.9    mM      0.9   mM    0.9   mMGlucose  22.0   mM      22.0  mM    22.0  mMCitrate  1.0    mM      1.9   mM    1.9   mMTrisodium    10.8   mM      10.8  mM    10.8  mMCitrateNa2 HPO4    1.9    mM      1.9   mM    --Histindine    --         --          22.0  mMpH       7.4    mM      7.4   mM    7.4   mMOsmolarity    298    mOsm    303   mOsm  313   mOsm______________________________________

              TABLE 2______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22 C. for 72 hours in CPD-Tyrode's.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       5(2)*Epinephrine     2(3)    24(8)Collagen  1(2)    26(2)  22(18)Arachidonate     18(5)   --     34       --Ionophore 31(8)   29(8)  27(7)    31(9)  --______________________________________ *mean (S.E.) of at least 3 determinations except for aggregations using arachidonate

              TABLE 3______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22 C. for 72 hours in CPD-Plasma.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       8(5)*Epinephrine     1(1)    40(4)Collagen  2(2)    43(3)  47(6)Arachidonate     21(2)   48     46       --Ionophore 40(2)   45(6)  40(4)    47(10) 46______________________________________ *mean (S.E.) of at least 3 determintions except for aggregations using arachidonate

              TABLE 4______________________________________Percent Platelet Aggregation After Storage of UnwashedPlatelets at 22 C. for 72 hours in CPD-Plasma   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       14(5)*Epinephrine     0(1)    40(2)Collagen  2(1)    43(2)  41(2)Arachidonate     27(3)   44(2)  43(5)    --Ionophore 47(5)   46(2)  39(2)    46(2)  44______________________________________ *mean (S.E.) of at least 7 determinations except for aggregations using arachidonate which are means of 3 determinations.

              TABLE 5______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22 C. for 72 hours in CPD-Tyrode's-Phosphate.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       7Epinephrine     0       38Collagen  2       47     41Arachidonate     28      40     39       38*Ionophore 40      45     42       46     38*______________________________________

              TABLE 6______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22 C. for 72 Hours in CPD-Tyrode's-Histidine.   First StimulusSecond                                   Arach-Stimulus  Saline  ADP    Epinephrine                             Collagen                                    idonate______________________________________Saline    0ADP       11Epinephrine     1       35Collagen 5     43      33Arachidonate     24*     42*    38*      33*Ionophore +       48     37       43     30*A23187______________________________________ *mean (S.E.) of at least 3 determinations except for aggregation using arachidonate + 2 experiments gave no aggregation with ionophore A23187 while one gave 36% aggregation. Normal platelet aggregation to ionophore A23187 were found in CPDTyrod' sPhosphate.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2786014 *Sep 10, 1952Mar 19, 1957James L TullisPlatelet preservation
US3629071 *Feb 10, 1970Dec 21, 1971Upjohn CoStorage-stable hemostatic transfusion suspensions of blood platelets, glucose, magnesium chloride and certain prostaglandins
US3729947 *Dec 4, 1970May 1, 1973Alza CorpProcess for storing blood platelets
US3735005 *Aug 19, 1970May 22, 1973Alza CorpMethod for preparing a viable platelet concentrate
US3753357 *Dec 14, 1970Aug 21, 1973Ovitron Res CorpMethod and apparatus for the preservation of cells and tissues
US3814687 *Jun 1, 1973Jun 4, 1974Honeywell IncBlood platelet separation
US3850174 *Mar 14, 1973Nov 26, 1974Becton Dickinson CoPlasma separator assembly
US4014993 *Nov 17, 1975Mar 29, 1977The Upjohn CompanyInhibition of platelet aggregation with substituted phenylhydratropic acid compounds
US4061537 *Jul 16, 1976Dec 6, 1977Behringwerke AktiengesellschaftPolyionic isotonic salt solution
US4148879 *Dec 23, 1977Apr 10, 1979Nelson Research & Development CompanyInhibition of platelet aggregation with selected phosphonic and phosphinic acid esters
US4152208 *Dec 6, 1977May 1, 1979Hoffmann-La Roche Inc.Stabilized leucocytes
US4267269 *Feb 5, 1980May 12, 1981Baxter Travenol Laboratories, Inc.Red cell storage solution
US4269718 *May 5, 1980May 26, 1981The Institutes Of Medical SciencesDisplacement of platelets from blood by injection of saline into outer end of chamber; purity
US4387031 *Jul 20, 1981Jun 7, 1983Luigi PrandiCentrifuging with polydimethylsiloxane and inert powdered polymer
US4390619 *Sep 28, 1981Jun 28, 1983James Clifford HaightAs buffer source
US4405719 *May 29, 1981Sep 20, 1983Coulter Electronics, Inc.Iodoacetamide, n-(2-acetamino) diacetic acid, penicillin derivative
US4455299 *Nov 20, 1981Jun 19, 1984Baxter Travenol Laboratories, Inc.Storage of blood platelets
GB1014712A * Title not available
GB1283273A * Title not available
Non-Patent Citations
Reference
1Abrahamsen, A. F., "A Modification of the Technique for 51 Cr-Labelling of Blood Platelets Giving Increased Circulating Platelet Radioactivity", Scand. J. Haemat. (1968), vol. 5, pp. 53-63.
2 *Abrahamsen, A. F., A Modification of the Technique for 51 Cr Labelling of Blood Platelets Giving Increased Circulating Platelet Radioactivity , Scand. J. Haemat. (1968), vol. 5, pp. 53 63.
3Adams, G. A. et al., "Serotonin Uptake by Stored Platelets", Thrombosis Research, (1982), vol. 28, pp. 281-284.
4 *Adams, G. A. et al., Serotonin Uptake by Stored Platelets , Thrombosis Research, (1982), vol. 28, pp. 281 284.
5Browdie, P. et al., "Stroma-Free Hemoglobin--Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits", The American Journal of Surgery, (1975), vol. 129, pp. 365-368.
6 *Browdie, P. et al., Stroma Free Hemoglobin Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits , The American Journal of Surgery, (1975), vol. 129, pp. 365 368.
7 *CA 77:59601q B. L. Tranum et al.: In vivo Survival of Platelets Prepared in CPD Anticoagulant, Transfusion, (1972), 12(3):168 74.
8CA 77:59601q--B. L. Tranum et al.: "In vivo Survival of Platelets Prepared in CPD Anticoagulant," Transfusion, (1972), 12(3):168-74.
9 *CA 94:448 728 E. P. Scott et al.: Viability and Function of Platelet Concentrates Stored in CPD Adenine (CPDA 1) , Transfusion, (1980), 20(J):489 97.
10CA 94:448 728--E. P. Scott et al.: "Viability and Function of Platelet Concentrates Stored in CPD-Adenine (CPDA-1)", Transfusion, (1980), 20(J):489-97.
11 *Chemical Abstracts 94:52751f, vol. 94, p. 356, (1981).
12 *Definition of Ringer s Injection, Ringer s Solution, Lactated Ringer s Injection, Anticoagulant Sodium Citrate Solution, Anticoagulant Acid and Citrate Dextrose Solution.
13Definition of Ringer's Injection, Ringer's Solution, Lactated Ringer's Injection, Anticoagulant Sodium Citrate Solution, Anticoagulant Acid and Citrate Dextrose Solution.
14Holme, S. et al., "Comparative Measurements of Platelet Size by Coulter Counter, Microscopy of Blood Smears, and Light-Transmission Studies", J. Lab. Clin. Med., (1981), vol. 97, No. 5, pp. 610-622.
15Holme, S. et al., "Platelet Storage at 22 C.: Effect of Type of Agitation on Morphology, Viability, and Function In Vitro", Blood, (1978), vol. 52, No. 2, pp. 425-435.
16 *Holme, S. et al., Comparative Measurements of Platelet Size by Coulter Counter, Microscopy of Blood Smears, and Light Transmission Studies , J. Lab. Clin. Med., (1981), vol. 97, No. 5, pp. 610 622.
17 *Holme, S. et al., Platelet Storage at 22 C.: Effect of Type of Agitation on Morphology, Viability, and Function In Vitro , Blood, (1978), vol. 52, No. 2, pp. 425 435.
18Kuchler, R. J., "Biochemical Methods in Cell Culture and Virology", (1977), published by Dowden, Hutchinson & Ross, Inc., pp. 83-90.
19 *Kuchler, R. J., Biochemical Methods in Cell Culture and Virology , (1977), published by Dowden, Hutchinson & Ross, Inc., pp. 83 90.
20Kunicki, T. J. et al., "A Study of Variables Affecting the Quality of Platelets Stored at `Room Temperature`", Transfusion, (1975), vol. 15, No. 5, pp. 414-421.
21 *Kunicki, T. J. et al., A Study of Variables Affecting the Quality of Platelets Stored at Room Temperature , Transfusion, (1975), vol. 15, No. 5, pp. 414 421.
22Lazzlo, J., "Energy Metabolism of Human Leukemic Lymphocytes and Granulocytes", Blood, (1967), vol. 30, No. 2, pp. 151-167.
23 *Lazzlo, J., Energy Metabolism of Human Leukemic Lymphocytes and Granulocytes , Blood, (1967), vol. 30, No. 2, pp. 151 167.
24 *Matsumoto Chem. Abst., vol. 91, (1979), p. 136,650y.
25Matsumoto--Chem. Abst., vol. 91, (1979), p. 136,650y.
26Murphy, S. et al., "Platelet Size and Kinetics in Hereditary and Acquired Thrombocytopenia", New England Journal of Medicine, (1972), vol. 286, pp. 499-504.
27Murphy, S. et al., "Platelet Storage at 22 C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability", Blood, (1975), vol. 46, No. 2, pp. 209-218.
28Murphy, S. et al., "Storage of Platelet Concentrates at 22 C.", Blood, (1970), vol. 35, No. 4, pp. 549-557.
29 *Murphy, S. et al., Platelet Size and Kinetics in Hereditary and Acquired Thrombocytopenia , New England Journal of Medicine, (1972), vol. 286, pp. 499 504.
30 *Murphy, S. et al., Platelet Storage at 22 C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability , Blood, (1975), vol. 46, No. 2, pp. 209 218.
31 *Murphy, S. et al., Storage of Platelet Concentrates at 22 C. , Blood, (1970), vol. 35, No. 4, pp. 549 557.
32Murphy, S., "Platelet Transfusion", Prog. Hemostasis Thromb., (1976), vol. 3, pp. 289-310.
33Murphy, S., "The Preparation and Storage of Platelets for Transfusions", Treatment of Bleeding Disorders by Mammen, Barnhart, Lusher and Walsh, (1980), pp. 303-313.
34 *Murphy, S., Platelet Transfusion , Prog. Hemostasis Thromb., (1976), vol. 3, pp. 289 310.
35 *Murphy, S., The Preparation and Storage of Platelets for Transfusions , Treatment of Bleeding Disorders by Mammen, Barnhart, Lusher and Walsh, (1980), pp. 303 313.
36Reitzer, L. J. et al., "Evidence That Glutamine, Not Sugar is the Major Energy Source for Cultured HeLa Cells", J. Biol. Chem., (1979), vol. 254, No. 8, pp. 2669-2676.
37Reitzer, L. J. et al., "The Pentose Cycle", J. Biol. Chem., (1980), vol. 255, No. 12, pp. 5616-5626.
38 *Reitzer, L. J. et al., Evidence That Glutamine, Not Sugar is the Major Energy Source for Cultured HeLa Cells , J. Biol. Chem., (1979), vol. 254, No. 8, pp. 2669 2676.
39 *Reitzer, L. J. et al., The Pentose Cycle , J. Biol. Chem., (1980), vol. 255, No. 12, pp. 5616 5626.
40Rock, G. A. et al., "Storage of Platelets Collected by Apheresis", Transfusion, (1983), vol. 23, No. 2, pp. 99-105.
41 *Rock, G. A. et al., Storage of Platelets Collected by Apheresis , Transfusion, (1983), vol. 23, No. 2, pp. 99 105.
42Rock, G. et al., "Platelet Storage: An Assessment of the Requirements for Plasma and Oxygen", Transfusion, (1981), vol. 21, No. 2, pp. 167-177.
43Rock, G. et al., "Storage of Platelets Obtained by Apheresis Techniques", Plasma Ther. Transfrs. Technol., (1982), vol. 3, pp. 305-308.
44 *Rock, G. et al., Platelet Storage: An Assessment of the Requirements for Plasma and Oxygen , Transfusion, (1981), vol. 21, No. 2, pp. 167 177.
45 *Rock, G. et al., Storage of Platelets Obtained by Apheresis Techniques , Plasma Ther. Transfrs. Technol., (1982), vol. 3, pp. 305 308.
46 *Sivertsen Chem. Abst., vol. 77, (1972), p. 73201r.
47Sivertsen--Chem. Abst., vol. 77, (1972), p. 73201r.
48Tegos, C. et al., "Platelet Glycolysis in Platelet Storage--III; The Inability of Platelets to Utilize Exogenous Citrate".
49 *Tegos, C. et al., Platelet Glycolysis in Platelet Storage III; The Inability of Platelets to Utilize Exogenous Citrate .
50Wise, B. M. et al., "The Continuous Growth of Vertebrate Cells in the Absence of Sugar", J. Biol. Chem., (1981), vol. 256, No. 15, pp. 7812-7819.
51 *Wise, B. M. et al., The Continuous Growth of Vertebrate Cells in the Absence of Sugar , J. Biol. Chem., (1981), vol. 256, No. 15, pp. 7812 7819.
52Wong, S. C. et al., "The Effect of Adenine on Platelet Storage", Transfusion, (1982), vol. 22, No. 4, pp. 283-287.
53 *Wong, S. C. et al., The Effect of Adenine on Platelet Storage , Transfusion, (1982), vol. 22, No. 4, pp. 283 287.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5147776 *Feb 26, 1990Sep 15, 1992University Of Iowa Research FoundationUse of 2,5-anhydromannitol for control of pH during blood storage
US5234808 *Oct 30, 1991Aug 10, 1993Thomas Jefferson UniversityPreservation of pH; storage stability
US5344752 *Apr 7, 1993Sep 6, 1994Thomas Jefferson UniversityPlasma-based platelet concentrate preparations
US5376524 *Dec 1, 1992Dec 27, 1994Thomas Jefferson UniversityAn aqueous solution for intravenous transfusion comprising a sugar, a phosphates and an acetates for promoting the formation of adenosine triphosphate
US5378601 *Jul 24, 1992Jan 3, 1995Montefiore Medical CenterMethod of preserving platelets with apyrase and an antioxidant
US5459030 *Jun 2, 1993Oct 17, 1995Steritech, Inc.Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5466573 *Aug 5, 1994Nov 14, 1995Thomas Jefferson UniversityPlatelet storage method in a medium containing acetate and phosphate
US5474891 *Jun 16, 1994Dec 12, 1995Thomas Jefferson UniversityPlasma-based platelet concentrate preparations with additive
US5482828 *Mar 7, 1994Jan 9, 1996Steritech, Inc.Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5569579 *Mar 17, 1994Oct 29, 1996Thomas Jefferson UniversitySynthetic-based platelet storage media
US5589395 *Apr 15, 1993Dec 31, 1996Behringwerke AktiengesellschaftMethod for stabilizing annexins
US5618662 *Jan 21, 1994Apr 8, 1997Cerus CorporationIntravenous administration of psoralen
US5709991 *Jun 7, 1995Jan 20, 1998Cerus CorporationProralen inactivation of microorganisms and psoralen removal
US5906915 *Oct 31, 1996May 25, 1999Baxter International Inc.Method for storing red cells using reduced citrate anticoagulant and a solution containing sodium, citrate, phosphate, adenine and mannitol
US6251580Jan 29, 1999Jun 26, 2001Lily LinPlatelet storage nutrient solution; for use in the purification of platelets
US6258577Jul 21, 1998Jul 10, 2001Gambro, Inc.Adding nontoxic amount of endogenous photosensitizer to fluid, exposing to photoradiation to activate sensitizer and allowing it to deactivate the microorganism; viral decontamination of blood and blood products
US6268120Oct 19, 1999Jul 31, 2001Gambro, Inc.Isoalloxazine derivatives to neutralize biological contaminants
US6277337Jul 20, 1999Aug 21, 2001Gambro, Inc.Microorganisms in fluids or on surfaces. preferably the fluids contain blood or blood products and comprise biologically active proteins.
US6277556Dec 17, 1998Aug 21, 2001Baxter International Inc.Controlling donor blood characteristics
US6326197Jan 24, 2000Dec 4, 2001Baxter International Inc.Platelet suspensions and methods for resuspending platelets
US6413713 *Oct 30, 1998Jul 2, 2002Hyperbaric SystemsMixing with gelatin; cooling; high pressure storage
US6548241Nov 28, 2000Apr 15, 2003Gambro, Inc.Storage solution containing photosensitizer for inactivation of biological contaminants
US6566046Dec 7, 2000May 20, 2003Baxter International Inc.Platelet storage media mixture of sodium chloride, sodium citrate, sodium acetate, sodium phosphate ans psoralen
US6613566Oct 26, 2001Sep 2, 2003Baxter International Inc.Platelet suspensions and methods for resuspending platelets
US6828323Feb 5, 2001Dec 7, 2004Gambro, Inc.Isoalloxazine derivatives to neutralize biological contaminants
US6866992 *Apr 14, 2003Mar 15, 2005Baxter International Inc.Aqueous solution comprising sodium chloride, sodium citrate, sodium acetate, sodium phosphate and a psoralen; stoichiometry, nonsettling of psoralen
US7029839Apr 22, 2004Apr 18, 2006Human BiosystemsCooling refrigeration preservation; freeze drying; washing with polyvinylpyrrolidone, calcium channel blocker, nucleoside, potassium chloride , polyoxyethylene glycol, amino acid and steroid
US7049110Feb 3, 2003May 23, 2006Gambro, Inc.Inactivation of West Nile virus and malaria using photosensitizers
US7094378Jun 15, 2000Aug 22, 2006Gambro, Inc.Method and apparatus for inactivation of biological contaminants using photosensitizers
US7183045Apr 24, 2003Feb 27, 2007Gambro Inc.Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution
US7202020Jun 9, 2004Apr 10, 2007Human Biosystemsincludes a preservation medium of plasma and a gel-former in a concentration such that the medium is in a sufficiently fluent state at 37 degrees C. to allow platelets to move within the medium and sufficiently gelatinous state at 5 degrees C. to prevent moving; suitable for direct transfusion
US7220747May 6, 2003May 22, 2007Gambro, Inc.Selected from the group consisting of alloxazines and photosensitizers
US7498156Jun 15, 2005Mar 3, 2009Caridianbct Biotechnologies, LlcUse of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7648699Aug 31, 2006Jan 19, 2010Caridianbct Biotechnologies, LlcPreventing transfusion related complications in a recipient of a blood transfusion
US7892535Dec 3, 2009Feb 22, 2011Caridianbct Biotechnologies, LlcPreventing transfusion related complications in a recipient of a blood transfusion
US7901673Aug 25, 2003Mar 8, 2011Caridianbct Biotechnologies, LlcBlood transfusion
US7985588Oct 31, 2007Jul 26, 2011Caridianbct Biotechnologies, LlcInactivating leukocytes in whole blood via inoculation with riboflavin and exposure to ultraviolet radiation; blood transfusions
US8679736Dec 17, 2009Mar 25, 2014Terumo Bct Biotechnologies, LlcRemoval of adenine during a pathogen reduction process in whole blood or red blood cells by dilution
US8835104Dec 18, 2008Sep 16, 2014Fenwal, Inc.Medium and methods for the storage of platelets
EP0510185A1 *Oct 30, 1991Oct 28, 1992Baxter IntBlood platelet storage medium.
WO1992008349A1 *Oct 30, 1991May 8, 1992Baxter IntBlood platelet storage medium
WO1994002015A1 *Jul 2, 1993Feb 3, 1994Montefiore Med CenterMethod of preserving platelets
WO1998056247A1 *May 15, 1998Dec 17, 1998Baxter IntPlatelet suspensions and methods for resuspending platelets
Classifications
U.S. Classification424/93.72, 435/2
International ClassificationA61K35/14, A01N1/02
Cooperative ClassificationA61K35/19, A01N1/02, A01N1/0226
European ClassificationA61K35/14, A01N1/02, A01N1/02C2P
Legal Events
DateCodeEventDescription
Oct 31, 1995FPAYFee payment
Year of fee payment: 12
Sep 30, 1991FPAYFee payment
Year of fee payment: 8
May 8, 1986ASAssignment
Owner name: ROCK, GAIL A., 270 SANDRIDGE RD., ROCKCLIFFE PARK,
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ADAMS, GEORGE A.;REEL/FRAME:004969/0252
Effective date: 19860502